Innovative Leukemia and Lymphoma Therapy

Gertjan J. L. KASPERS is Professor and Head of the Division of Oncology/Hematology, VU University Medical Center, Amsterdam, Netherlands. Dr. Kaspers received his M.D. from the Vrije Universiteit, Amsterdam, Netherlands, and his Ph.D. from the VU University Medical Center, Amsterdam, Netherlands. His current research covers a randomized phase III study on the treatment of children and adolescents with refractory or relapsed acute myeloid leukemia, a phase II study on Mylotarg in childhood relapsed and refractory AML, an international study on the treatment of Pediatric Acute Promyelocytic Leukemia, clinical phase II studies with clofarabine-containing regimens in pediatric acute myeloid leukemia, and a clinical phase II study with bortezomib in pediatric acute lymphoblastic leukemia in preparation.BERTRAND COIFFIER is Professor and Chief of Hematology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon and Claude-Bernard University, Pierre-Benite, France. Dr. Coiffier has written more than 300 publications in internationally recognized, leading journals in the field of hematology on lymphomas, lymphoproliferative diseases, chemotherapy, high-dose therapy, and autotransplant, biological response modifiers.MICHAEL C. HEINRICH is Professor of Medicine, Oregon Health & Science University, Division of Hematology & Medical Oncology, Portland, Oregon, USA; Chairman, Portland VA Medical Center Tumor Board, Section Chief, Hematology Oncology, Portland VA Hematology/Medical Oncology Service, Portland, Oregon, USA; and Interim Head, Hematology & Medical Oncology, Oregon Health & Science University, Portland, Oregon, USA. Dr. Heinrich received his M.D. from the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. ELIHU ESTEY is Professor of Hematology in the Division of Medicine at the University of Washington Medical Center and a Member at the Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. Dr. Estey received his A.B. from Yale University, New Haven, Connecticut, USA, and his M.D. from Johns Hopkins University, Baltimore, Maryland, USA.

• Foreword, Preface, Contributors, 1. Gene Expression Profiling to Detect New Treatment Targets in Leukemia and Lymphoma: A Future Perspective, 2. Individualized Tumor Response Testing in Leukemia and Lymphoma, 3. Minimal Residual Disease, 4. New Methods for Clinical Trials: AML as an Example, 5. Monoclonal Antibody Mediated Treatment in Acute Myeloid Leukemia, 6. Monoclonal Antibodies in the Treatment of Malignant Lymphomas and Chronic Lymphocytic Leukemia, 7. Radioimmunotherapy of Hematological Malignancies, 8. Differentiation Induction in Acute Promyelocytic Leukemia, 9. DNA Methylation and Epigenetics: New Developments in Biology and Treatment, 10. The Emerging Role of Histone Deacetylase Inhibitors in the Treatment of Lymphoma, 11. Antileukemic Treatment Targeted at Apoptosis Regulators, 12. Angiogenesis in Hematological Malignancies, 13. Nucleic Acid-Based, mRNA-Targeted Therapeutics for Hematologic Malignancies, 14. Active Specific Immunization by the Use of Leukemic Dendritic Cell Vaccines, 15. CDK Inhibitors in Leukemia and Lymphoma, 16. FLT3: A Receptor Tyrosine Kinase Target in Adult and Pediatric AML, 17. Treatment of Chronic Myeloid Leukemia with Bcr-Abl Kinase Inhibitors, 18. Tyrosine Kinase Inhibitors: Targets Other Than FLT3, BCR-ABL, and c-KIT, 19. Tyrosine Phosphatases as New Treatment Targets in Acute Myeloid Leukemia, 20. Proteasome and Protease Inhibitors, 21. Farnesyltransferase Inhibitors: Current and Prospective Development for Hematologic Malignancies, 22. Targeting Notch Pathways, 23. mTOR Targeting Agents for the Treatment of Lymphoma and Leukemia, 24. Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning, 25. Modulation of Classical Multidrug Resistance and Drug Resistance in General, Index